An international clinical research consortium has reported recommendations on endpoints and design of clinical trials in USH2A-related retinal degenerations. The study, supported by the US… Read More »Endpoints and clinical trial design for IRDs and USH2A reporting outcomes from a natural history study.
Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.
Dear EURETINA Members, A very warm welcome to the October 10th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »October 10th, 2024 “EURETINA-Brief”© Issue No. 301
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital NHS Foundation Trust, UK, have reported a study on CNG3A-associated achromatopsia (ACMH),… Read More »CNGA3-associated ACHM displays stable foveal cone structure over time, presenting an attractive therapeutic opportunity for treatment.
EURETINA Congress, Barcelona – Sept. 20th, 2024: Prof. M. Dominick Fischer, based at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital,… Read More »Real world data from the treatment by voretigene neparvovec (Luxturna) of LCA2-RPE65 patients across 24 countries.
Delegates at the EURETINA Congress in Barcelona (Sept. 20th 2024) have heard new outcome data from a real-world study on faricimab (anti-VEGF, Vabymso), for naïve… Read More »Roche supported by a real-world study with initial outcomes on faricimab at EURETINA Congress – treatment-naïve patients with nAMD and DME (VOYAGER Study).
Dear EURETINA Members, A very warm welcome to the September 27th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »September 27th, 2024 “EURETINA-Brief”© Issue No. 300
Sept. 19th, 2024 – On the first day of the EURETINA Congress in Barcelona, Prof. Anat Loewenstein, President of EURETINA was delighted to announce the… Read More »EURETINA announce the inaugural Ramin Tadayoni Award for Dr. Andrea Govetto, MD, PhD, based in Milan, Italy.
Researchers at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital, NHS Foundation Trust, has reported that a surrogate biomarker (comprising the… Read More »Clinical trial endpoints use EZ and ELM biomarkers for selecting patients for treatments on X-linker retinitis pigmentosa.
HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.
